REG - Yourgene Health PLC - Directorate Change

Yourgene HealthAnnouncement

25/01/2022 07:05

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220125:nRSY4526Za&default-theme=true

RNS Number : 4526Z  Yourgene Health PLC  25 January 2022

Yourgene Health plc

("Yourgene" or the "Group" or the "Company")

 

Directorate Change

 

Manchester, UK - 25 January 2022: Yourgene (AIM: YGEN), a leading
international molecular diagnostic group, announces the appointment of Mary
Tavener as a Non-executive Director ("NED") and Chair of the Audit Committee
at Yourgene with effect from today.

 

Mary has extensive experience in the healthcare sector, having previously been
Chief Financial Officer and board member of AIM listed Advanced Medical
Solutions plc ("AMS") for 19 years during which the company saw 15 years of
consecutive growth. Mary is a Member of the Chartered Institute of Management
Accountants (ACMA) and a Fellow of the Association of Corporate Treasurers
(FCT). Mary has a degree in Chemistry from the University of Oxford.

 

Mary is also a Senior Independent NED of Abingdon Health and NED for Allergy
Therapeutics plc.

 

Separately the Group announces that Nick Mustoe has left the Board with
immediate effect. We wish to thank Nick for all his support during his time at
Yourgene and wish him the best for the future.

 

Adam Reynolds, Non-Executive Chairman, commented: "Mary has extensive
experience within the life sciences sector on AIM, which will be invaluable to
the Group as we grow and expand. I look forward to working alongside Mary as
we continue to engage with our extensive pipeline of exciting opportunities.

 

"I would also like to thank Nick for his time and support of the Group. Nick
has worked with Yourgene since the Company's IPO in 2014 and we have greatly
benefitted from his expertise and guidance. Nick remains a supportive
shareholder in Yourgene and I wish him all the best in his future endeavours."

 

Disclosures in accordance with the AIM Rules

 

Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the
following information is disclosed in respect of Mary Geraldine Tavener (aged
60):

 

 Current appointments      Former appointments in the last 5 years
 Abingdon Health PLC       Advanced Medical Solutions Group plc
 Allergy Therapeutics PLC  Advanced Healthcare Systems Ltd
                           Advanced Medical Solutions (Europe) Ltd
                           Advanced Medical Solutions (Plymouth) Ltd
                           Advanced Medical Solutions (UK) Ltd
                           Advanced Medical Solutions BV
                           Advanced Medical Solutions Germany GmBH
                           Advanced Medical Solutions Limited
                           Advanced Medical Solutions USA inc
                           AMS Trustee Company Ltd
                           Cuddington and Sandiway Playing Fields Association Ltd
                           Innovative Technologies Limited
                           Medlogic Global Holdings Ltd
                           MPN Medizin Produkte Neustadt GmBH
                           Resorba Medical GmBH

 

Mary Tavener does not hold any share or options in the Company.

 

There are no further disclosures required in accordance with AIM Rule 17 and
Schedule Two paragraph (g) of the AIM Rules for Companies.

 

 Yourgene Health plc                              Tel: +44 (0)161 669 8122

 Lyn Rees, Chief Executive Officer                investors@yourgene-health.com (mailto:investors@yourgene-health.com)
 Barry Hextall, Chief Financial Officer
 Joanne Cross, Director of Marketing

 Singer Capital Markets (Joint Corporate Broker)  Tel: +44 (0)20 7496 3000
 Aubrey Powell / Tom Salvesen / George Tzimas

 Stifel Nicolaus Europe Limited (Joint Corporate Broker)                               Tel: +44 (0)20 7710 7600
 Nicholas Moore / Matthew Blawat / Ben Maddison

 Walbrook PR Ltd (Media and Investor Relations)   Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
                                                  (mailto:yourgene@walbrookpr.com)
 Paul McManus / Alice Woodings                    Mob: 07980 541 893 / 07407 804 654

 

 

About Yourgene Health

 

Yourgene Health is an international molecular diagnostics group which develops
integrated genomic technologies and services enabling precision medicine. The
group works in partnership with global leaders in DNA technology to advance
diagnostic science.

 

Yourgene primarily develops, manufactures, and commercialises simple and
accurate molecular diagnostic solutions, for reproductive health, precision
medicine and now infectious diseases. The Group's flagship products include
non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic
disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests,
and a recent extension into the oncology space with DPYD genotyping.

 

The launch of Yourgene Genomic Services has enabled Yourgene to offer a global
laboratory service network equipped to be a full life-cycle partner for
clinical, research and pharmaceutical organisations to support partners at the
preclinical, clinical, and post-market stages to develop, manufacture, obtain
regulatory approval and commercialise new products and services. In addition,
Yourgene Genomic Services offers an NIPT and high throughput COVID testing
service.

 

In August 2020, Yourgene acquired Coastal Genomics, Inc., a sample preparation
technology company based in Vancouver, Canada, enabling the Company to extend
its offering and IP portfolio in the DNA sample preparation sector. The
acquisition increased Yourgene's geographical penetration into the US and
Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.

 

Yourgene Health is headquartered in Manchester, UK with offices in Taipei,
Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM
market under the ticker "YGEN". For more information visit
www.yourgene-health.com (http://www.yourgene-health.com/) and follow us on
twitter @Yourgene_Health.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAGZGZMGDLGZZZ